Scores here are heuristic signals about sourcing and corroboration across outlets — not verdicts on whether a story is true, and not an endorsement or condemnation of any outlet. How this works
A phase 2/3 clinical trial of BioNTech’s mRNA cancer immunotherapy BNT113 has
1
independent outlets · 100% owner-diverse
Save this story
Connect "BioNTech’s mRNA cancer vaccine fails phase 3 test, significantly denting analysts’ confidence - Fierce Biotech" to your own research notes and market positions — Next Level Intelligence links what you save to the assets and notes it actually affects.